Health Tech Capitol | Cellular Dynamics developing therapies
15492
post-template-default,single,single-post,postid-15492,single-format-standard,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Cellular Dynamics developing therapies

02 Sep Cellular Dynamics developing therapies

Posted at 15:44h in Uncategorized by
0 Likes

Cellular Dynamics International Inc., a Madison developer and manufacturer of human cells, said it plans to enter clinical trials with stem cell therapies sometime between 2018 and 2020.

The cell-maker revealed its plans in an announcement that it has split its operations into two business units — one focused on developing therapies and the other focused on building the company’s research products business.

The therapeutics division is headed by Emile Nuwaysir, CDI’s president and chief operating officer. It is focused on developing and bringing to market induced pluripotent stem cell — or iPSC-based therapies for eyes, hearts, Parkinson’s disease and cancer, CDI said. The company expects to file applications to conduct clinical trials in all of those areas in the 2018 to 2020 time period, it said.

Read more at the Milwaukee Journal Sentinel

No Comments

Sorry, the comment form is closed at this time.